Equity vs. Debt Financing: Updated for 2022 Market Conditions
By

The Covid-19 pandemic of the past two years, spiking inflation, and supply chain disruptions have created an economic situation that is putting increasing pressure on companies.  Many CFOs have never experienced rising interest rates, high inflation, or recession, all at the same time.  But those of us who have (myself…Read More

Read More
“Speed to Exit”: How to Get an IPO Closed in Record Time
By

We’ve all heard the phrase “Speed to Market.”  But how many have heard “Speed to Exit?”  Maybe not many, since I just created it but it really is a phrase that should be part of every CFO’s vocabulary.  Speed to exit is the driving force to get a liquidity event,…Read More

Read More
Fundraising Choices in Life Sciences: What, When & Why?
By

This article is the second in a two-part series about fundraising strategies for life science companies. In our last article, A Menu of Financing Alternatives for Life Science Companies, we looked at the continuum of choices available to life science companies who are actively engaged in fundraising to power up…Read More

Read More
A Menu of Financing Alternatives for Life Science Companies
By

This article is the first in a two-part series about fundraising strategies for life science companies. A Menu of Financing Alternatives for Life Science Companies Fundraising Choices in Life Sciences: What, When & Why? Life science companies, from emerging to evolved, therapeutics to diagnostics, solo or partnered, are constantly fundraising….Read More

Read More